SCHEMBL11028611

SCHEMBL11028611

Cc1ccccc1-c1cnc(C(N)=O)c(Nc2ccc(N3CCN(C)CC3)cc2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC2A1 P11166 3/20 0.51
▸ CDK4 P11802 2/20 0.51
▸ CCND1 P24385 1/20 0.51
▸ INSR P06213 1/20 0.50
▸ ALK Q9UM73 1/20 0.50
▸ MAPKAPK2 P49137 3/20 0.48
▸ PIM1 P11309 1/20 0.47
▸ TTK P33981 1/20 0.47
▸ PIM2 Q9P1W9 1/20 0.47
▸ CCNA2 P20248 2/20 0.47
▸ CDK2 P24941 2/20 0.47
▸ CCND3 P30281 2/20 0.47
▸ CDK6 Q00534 2/20 0.47
▸ CCNK O75909 1/20 0.47
▸ CDK9 P50750 1/20 0.47
▸ ADRA2A P08913 3/20 0.47
▸ ADRA2C P18825 3/20 0.47
▸ ADRA2B P18089 2/20 0.47
▸ LCK P06239 2/20 0.47
▸ KDR P35968 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11033766 0.89 SLC2A1 (0.51) SLC2A1CDK4CCND1INSRALK
SCHEMBL11031519 0.89 SLC2A1 (0.57) SLC2A1CDK4CCND1INSRALK
SCHEMBL11029599 0.89 MAPKAPK2 (0.58) SLC2A1CDK4CCND1INSRALK
SCHEMBL27922264 0.87 SLC2A1 (0.49) SLC2A1CDK4INSRALKMAPKAPK2
SCHEMBL11033969 0.87 SLC2A1 (0.56) SLC2A1CDK4INSRALKMAPKAPK2
SCHEMBL11028125 0.86 ALK (0.56) SLC2A1CDK4INSRALKMAPKAPK2
SCHEMBL11026741 0.84 FYN (0.55) SLC2A1CDK4CCND1MAPKAPK2CCNA2
SCHEMBL11029346 0.84 MAPKAPK2 (0.61) SLC2A1CDK4CCND1INSRALK
SCHEMBL11031445 0.84 SLC2A1 (0.51) SLC2A1CDK4CCND1MAPKAPK2CCNA2
SCHEMBL11029285 0.83 SLC2A1 (0.49) SLC2A1CDK4CCND1INSRALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US claimed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US claimed
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US disclosed
EP-2665711-A1 PICOLINAMIDE INHIBITORS OF KINASES Abbvie Inc. (US) 2013-11-27 — — EP disclosed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US disclosed
WO-2012100135-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ALK, PKN2, ERBB2 SLC2A1 3662/4885CDK4 78/4885CCND1 547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback